pramipexole has been researched along with Parkinsonian Disorders in 47 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 19 (40.43) | 29.6817 |
| 2010's | 23 (48.94) | 24.3611 |
| 2020's | 5 (10.64) | 2.80 |
| Authors | Studies |
|---|---|
| Belloso-Iguerategui, A; Cotman, CW; Fernández-Irigoyen, J; Gago, B; Merino-Galan, L; Prieto, GA; Quiroga-Varela, A; Rodríguez-Chinchilla, T; Rodríguez-Oroz, MC; Santamaria, E; Zamarbide, M | 1 |
| Martinez, E; Météreau, É; Pasquereau, B; Saga, Y; Tremblay, L | 1 |
| Belloso-Iguerategui, A; Delgado-Alvarado, M; Gago, B; Jiménez-Urbieta, H; Marin, C; Merino-Galán, L; Navalpotro-Gómez, I; Quiroga-Varela, A; Rodríguez-Chinchilla, T; Rodríguez-Oroz, MC | 1 |
| Frucht, S; Han, SC; Katus, L | 1 |
| Costa, G; Marongiu, J; Morelli, M; Serra, M; Simola, N | 1 |
| Chassain, C; Dardou, D; Durif, F; Reyrolle, L | 1 |
| Chen, NH; Heng, Y; Huang, JY; Mou, Z; Yuan, YH; Zhang, QS | 1 |
| Belloso-Iguerategui, A; Delgado-Alvarado, M; Fernagut, PO; Gago, B; Jiménez-Urbieta, H; Marin, C; Merino-Galán, L; Navalpotro-Gómez, I; Oregi, A; Quiroga-Varela, A; Rodríguez-Chinchilla, T; Rodríguez-Oroz, MC | 1 |
| Aguilera, J; Limón, ID; Martínez, I; Mendieta, L; Montes, S; Parra, I; Patricio, F; Pérez-Severiano, F; Tizabi, Y | 1 |
| Dutta, A; Rana, S; Talukdar, A; Talukdar, P | 1 |
| Ishii, K; Katayama, Y; Nagayama, H; Nakajima, N; Nishiyama, Y; Ueda, M | 1 |
| Bonastre, M; Cortés, R; Giralt, A; Marin, C; Mengod, G; Obeso, JA; Schapira, AH | 1 |
| Abe, H; Arimori, K; Ikeda, T; Ishida, Y; Koganemaru, G; Yasuda, K | 1 |
| Chiu, WH; Depboylu, C; Hermanns, G; Höglinger, GU; Maurer, L; Oertel, WH; Ries, V; Windolph, A | 1 |
| Nishinaka, K; Sawamura, M; Sekiya, T; Toma, K; Udaka, F; Unai, Y | 1 |
| Hiratochi, M; Ijiro, T; Kaidoh, K; Oana, F; Suzuki, T; Tsuchioka, A; Yamauchi, Y | 1 |
| Jeon, BS; Park, H; Park, SH; Shin, JH | 1 |
| Berghauzen-Maciejewska, K; Domin, H; Głowacka, U; Kosmowska, B; Ossowska, K; Śmiałowska, M; Wardas, J | 1 |
| Grasso, SA; Holtz, NA; Napier, TC; Persons, AL; Tedford, SE | 1 |
| Ferrario, JE; Gershanik, OS; Larramendy, C; Murer, MG; Saborido, MD; Taravini, IR | 1 |
| Fukuyama, H; Hashikawa, K; Hattori, N; Kohriyama, T; Matsumoto, M; Ohshita, T; Takahashi, T; Yamashita, H | 1 |
| Aigner, L; Aigner, R; Buerger, E; Desplats, P; Hagl, C; Karl, A; Klucken, J; Laemke, J; Masliah, E; Ploetz, S; Winkler, J; Winner, B | 1 |
| Ariga, H; Inden, M; Kitamura, Y; Shibaike, T; Taira, T; Takata, K; Tamaki, A; Taniguchi, T; Yamamoto, A; Yanagida, T; Yasui, H | 1 |
| Ahn, YH; Lee, PH; Park, HJ; Shin, JY | 1 |
| Marti, M; Morari, M; Viaro, R | 1 |
| Buck, K; Buerger, E; Ferger, B; Koros, E; Shimasaki, M; Voehringer, P | 1 |
| de la Fuente-Fernández, R; Dinelle, K; Doudet, DJ; Mak, E; Schulzer, M; Sossi, V | 1 |
| Brioschi, A; Mauro, A; Pignatti, R; Semenza, C; Wenter, J; Zamarian, L | 1 |
| Ahmed, SH; Bezard, E; Engeln, M; Fernagut, PO; Tison, F; Vouillac, C | 1 |
| Miwa, H; Nakayama, Y | 1 |
| Bagetta, V; Calabresi, P; Del Papa, G; Gardoni, F; Ghiglieri, V; Giampà, C; Pendolino, V; Picconi, B; Sgobio, C; Tozzi, A; Zianni, E | 1 |
| Chen, CY; Chow, KC; Lin, CY; Lin, SF; Yeh, CH | 1 |
| Alkhater, RA; Minassian, BA; Rilstone, JJ | 1 |
| Schapira, AH | 1 |
| Albin, RL; Desmond, TJ; Frey, KA; Kemmerer, ES; Kilbourn, MR | 1 |
| Bernauer, E; Finsterer, J | 1 |
| Kanzato, N; Murao, H; Nishihira, T; Takara, H | 1 |
| Anderson, DW; Bradbury, KA; Schneider, JS | 1 |
| Cantú-Martínez, L; Flores, Lde L; González, HC; Martínez, HR; Onofre-Castillo, J; Villarreal, HJ | 1 |
| de Freitas, GR; Fontenelle, LF; Garcia, RF; Mendlowicz, MV; Nazar, BP; Ordacgi, L; Rosso, AL | 1 |
| Brecht, HM; Köster, J; Kraus, PH; Odin, P; Reichmann, H | 1 |
| Ondo, W; Tan, EK | 1 |
| Carvey, PM; Chen, EY; Ling, ZD; Lipton, JW; Ma, SY; Robie, HC; Tong, CW; Vu, TQ | 1 |
| Brannan, T; Prikhojan, A; Yahr, MD | 1 |
| Anderson, DW; Neavin, T; Schneider, JS; Smith, JA | 1 |
| Montastruc, JL; Rascol, O | 1 |
| Dallocchio, C; Mazzarello, P | 1 |
1 review(s) available for pramipexole and Parkinsonian Disorders
| Article | Year |
|---|---|
Dopamine agonists and neuroprotection in Parkinson's disease.
Topics: Animals; Antioxidants; Benzothiazoles; Disease Models, Animal; Dopamine Agonists; Environmental Exposure; Humans; Neuroprotective Agents; Neurotoxins; Parkinson Disease; Parkinsonian Disorders; Pramipexole; Thiazoles | 2002 |
46 other study(ies) available for pramipexole and Parkinsonian Disorders
| Article | Year |
|---|---|
Hippocampal synaptic failure is an early event in experimental parkinsonism with subtle cognitive deficit.
Topics: alpha-Synuclein; Animals; Cognition; Dopamine; Dopaminergic Neurons; Hippocampus; Humans; Levodopa; Neurotransmitter Agents; Parkinson Disease; Parkinsonian Disorders; Pramipexole; Rats | 2023 |
The anterior caudate nucleus supports impulsive choices triggered by pramipexole.
Topics: Animals; Benzothiazoles; Dopamine Agonists; Haplorhini; Impulsive Behavior; Parkinson Disease; Parkinsonian Disorders; Pramipexole; Reward; Ventral Striatum | 2020 |
Motor impulsivity and delay intolerance are elicited in a dose-dependent manner with a dopaminergic agonist in parkinsonian rats.
Topics: Animals; Corpus Striatum; Disruptive, Impulse Control, and Conduct Disorders; Dopamine; Dopamine Agonists; Dose-Response Relationship, Drug; Impulsive Behavior; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Pramipexole; Rats; Rats, Sprague-Dawley | 2020 |
Dramatic Response to Pramipexole in Delayed-Onset Parkinsonism from Osmotic Demyelinating Syndrome.
Topics: Adult; Antiparkinson Agents; Deamino Arginine Vasopressin; Demyelinating Diseases; Dystonia; Epistaxis; Hemostatics; Humans; Hyponatremia; Levodopa; Locked-In Syndrome; Male; Myelinolysis, Central Pontine; Osmotic Pressure; Parkinsonian Disorders; Postoperative Hemorrhage; Pramipexole; Pseudobulbar Palsy; Rhinoplasty; Tetrahydronaphthalenes; Thiophenes; Treatment Failure; Treatment Outcome; von Willebrand Disease, Type 1 | 2020 |
Increased emissions of 50-kHz ultrasonic vocalizations in hemiparkinsonian rats repeatedly treated with dopaminomimetic drugs: A potential preclinical model for studying the affective properties of dopamine replacement therapy in Parkinson's disease.
Topics: Affect; Animals; Apomorphine; Desipramine; Disease Models, Animal; Dopamine Agents; Levodopa; Male; Parkinsonian Disorders; Pramipexole; Rats; Rats, Sprague-Dawley; Ultrasonic Waves; Vocalization, Animal | 2021 |
Chronic pramipexole treatment induces compulsive behavior in rats with 6-OHDA lesions of the substantia nigra and ventral tegmental area.
Topics: Animals; Antiparkinson Agents; Benzothiazoles; Compulsive Behavior; Corpus Striatum; Frontal Lobe; Immunohistochemistry; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Pramipexole; Proto-Oncogene Proteins c-fos; Random Allocation; Rats, Sprague-Dawley; Substantia Nigra; Ventral Tegmental Area | 2017 |
Reassessment of subacute MPTP-treated mice as animal model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antiparkinson Agents; Astrocytes; Behavior, Animal; Benserazide; Benzothiazoles; Blood-Brain Barrier; Chromatography, High Pressure Liquid; Corpus Striatum; Disease Models, Animal; Drug Combinations; Levodopa; Male; Mice; Mice, Inbred C57BL; Microscopy, Electron; Parkinsonian Disorders; Pramipexole; Selegiline | 2017 |
Pramipexole-induced impulsivity in mildparkinsonian rats: a model of impulse control disorders in Parkinson's disease.
Topics: Animals; Corpus Striatum; Disruptive, Impulse Control, and Conduct Disorders; Dopamine; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Impulsive Behavior; Motor Activity; Parkinson Disease; Parkinsonian Disorders; Pramipexole; Rats; Substantia Nigra | 2019 |
Effectiveness of Fragment C Domain of Tetanus Toxin and Pramipexole in an Animal Model of Parkinson's Disease.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Antiparkinson Agents; Astrocytes; Corpus Striatum; Drug Therapy, Combination; Gliosis; Male; Microglia; Motor Activity; Oxidative Stress; Oxidopamine; Parkinsonian Disorders; Peptide Fragments; Pramipexole; Random Allocation; Rats, Wistar; Tetanus Toxin; Time Factors | 2019 |
Catatonia and parkinsonism as a sequelae of typhoid fever: a rare experience.
Topics: Adolescent; Amantadine; Antiparkinson Agents; Antipsychotic Agents; Benzodiazepines; Benzothiazoles; Catatonia; Humans; Hypnotics and Sedatives; Lorazepam; Male; Olanzapine; Parkinsonian Disorders; Pramipexole; Typhoid Fever | 2013 |
Therapeutic response to pramipexole in a patient with multiple system atrophy with predominant parkinsonism: positron emission tomography and pharmacokinetic assessments.
Topics: Antiparkinson Agents; Benzothiazoles; Brain; Comorbidity; Dose-Response Relationship, Drug; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Multiple System Atrophy; Parkinsonian Disorders; Positron-Emission Tomography; Pramipexole; Treatment Outcome | 2013 |
Early L-dopa, but not pramipexole, restores basal ganglia activity in partially 6-OHDA-lesioned rats.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Benserazide; Benzothiazoles; Corpus Striatum; Hippocampus; Levodopa; Male; Motor Activity; Neurogenesis; Oxidopamine; Parkinsonian Disorders; Pramipexole; Random Allocation; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D3; Substantia Nigra; Time Factors | 2014 |
Pramipexole reduces parkinsonian tremor induced by pilocarpine infusion in the rat striatum.
Topics: Animals; Antiparkinson Agents; Apomorphine; Benzothiazoles; Disease Models, Animal; Infusions, Intraventricular; Injections, Intraperitoneal; Male; Parkinsonian Disorders; Pilocarpine; Pramipexole; Rats; Rats, Sprague-Dawley; Ventral Striatum | 2015 |
Long-term treatment with L-DOPA or pramipexole affects adult neurogenesis and corresponding non-motor behavior in a mouse model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Anxiety; Benzothiazoles; Depression; Hippocampus; Levodopa; Male; Mice, Inbred C57BL; Neurogenesis; Neurons; Olfactory Bulb; Oxidopamine; Parkinsonian Disorders; Pramipexole; Random Allocation | 2015 |
[A case of Parkinson's disease following restless genial sensation].
Topics: Benzothiazoles; Clonazepam; Drug Therapy, Combination; Female; Humans; Middle Aged; Parkinsonian Disorders; Pramipexole; Restless Legs Syndrome; Sexual Dysfunctions, Psychological; Treatment Outcome | 2015 |
Duration of drug action of dopamine D2 agonists in mice with 6-hydroxydopamine-induced lesions.
Topics: Animals; Antiparkinson Agents; Apomorphine; Azepines; Benzothiazoles; Cabergoline; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Ergolines; Indoles; Injections, Intraventricular; Male; Mice; Motor Activity; Oxidopamine; Parkinsonian Disorders; Pramipexole; Quinolines; Receptors, Dopamine D2; Tetrahydronaphthalenes; Thiophenes | 2015 |
A patient with 41 CAG repeats in SCA17 presenting with parkinsonism and chorea.
Topics: Amantadine; Antiparkinson Agents; Benzothiazoles; Brain; Chorea; Humans; Levodopa; Male; Middle Aged; Parkinsonian Disorders; Positron-Emission Tomography; Pramipexole; Spinocerebellar Ataxias; TATA-Box Binding Protein; Trinucleotide Repeats | 2016 |
Adaptive down-regulation of the serotonin transporter in the 6-hydroxydopamine-induced rat model of preclinical stages of Parkinson's disease and after chronic pramipexole treatment.
Topics: Animals; Antiparkinson Agents; Benzothiazoles; Brain; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Dopaminergic Neurons; Dorsal Raphe Nucleus; Down-Regulation; Male; Neostriatum; Oxidopamine; Parkinsonian Disorders; Pramipexole; Radionuclide Imaging; Rats; Rats, Wistar; Serotonergic Neurons; Serotonin Plasma Membrane Transport Proteins; Tryptophan Hydroxylase; Tyrosine 3-Monooxygenase | 2016 |
Pharmacologically distinct pramipexole-mediated akinesia vs. risk-taking in a rat model of Parkinson's disease.
Topics: Animals; Antidepressive Agents, Tricyclic; Antiparkinson Agents; Benzothiazoles; Corpus Striatum; Delay Discounting; Dopamine Agonists; Dose-Response Relationship, Drug; Impulsive Behavior; Male; Mianserin; Mirtazapine; Motor Activity; Oxidopamine; Parkinsonian Disorders; Pramipexole; Random Allocation; Rats, Sprague-Dawley; Risk-Taking; Self Stimulation | 2016 |
Cabergoline and pramipexole fail to modify already established dyskinesias in an animal model of parkinsonism.
Topics: Amphetamine; Animals; Antiparkinson Agents; Behavior, Animal; Benzothiazoles; Cabergoline; Disease Models, Animal; Dopamine Antagonists; Drug Interactions; Dyskinesia, Drug-Induced; Ergolines; Female; Levodopa; Mesencephalon; Oxidopamine; Parkinsonian Disorders; Pramipexole; Rats; Rats, Wistar; Stereotyped Behavior; Tyrosine 3-Monooxygenase | 2008 |
[Case of a 30-year history of PARK6 --findings from functional imaging of the brain].
Topics: Antiparkinson Agents; Benzothiazoles; Diagnostic Imaging; Female; Humans; Levodopa; Middle Aged; Mutation, Missense; Parkinsonian Disorders; Pramipexole; Protein Kinases; Receptors, Dopamine D2; Time Factors | 2008 |
Dopamine receptor activation promotes adult neurogenesis in an acute Parkinson model.
Topics: Animals; Benzothiazoles; Bromodeoxyuridine; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Dopamine Agonists; ErbB Receptors; Exploratory Behavior; Eye Proteins; Functional Laterality; Gene Expression Regulation; Homeodomain Proteins; Lateral Ventricles; Male; Neurogenesis; Neurons; Olfactory Bulb; Oxidopamine; Paired Box Transcription Factors; Parkinsonian Disorders; PAX6 Transcription Factor; Phosphopyruvate Hydratase; Pramipexole; Proliferating Cell Nuclear Antigen; Rats; Rats, Inbred F344; Receptors, Dopamine D2; Receptors, Dopamine D3; Repressor Proteins; RNA, Messenger | 2009 |
Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice.
Topics: alpha-Synuclein; Animals; Antiparkinson Agents; Apoptosis; Benzothiazoles; Cell Line, Tumor; Corpus Striatum; Cytochromes c; Dopamine; Dose-Response Relationship, Drug; Humans; Hydrogen Peroxide; Hydroxyl Radical; Male; Mice; Mice, Inbred C57BL; Nerve Degeneration; Neural Pathways; Neurotoxins; Oxidative Stress; Parkinsonian Disorders; Pramipexole; Proto-Oncogene Proteins c-bcl-2; Rotenone; Substantia Nigra; Uncoupling Agents | 2009 |
Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
Topics: Animals; Antiparkinson Agents; bcl-2-Associated X Protein; Benzothiazoles; Cell Count; Disease Models, Animal; Dopamine; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation; Glutathione; Levodopa; Male; Mice; Mice, Inbred C57BL; Neurons; Parkinsonian Disorders; Pramipexole; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Statistics, Nonparametric; Substantia Nigra; Tyrosine 3-Monooxygenase | 2009 |
Dual motor response to l-dopa and nociceptin/orphanin FQ receptor antagonists in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) treated mice: Paradoxical inhibition is relieved by D(2)/D(3) receptor blockade.
Topics: Amisulpride; Animals; Antiparkinson Agents; Benzimidazoles; Benzothiazoles; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Drug Interactions; Drug Synergism; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Neural Inhibition; Nociceptin; Opioid Peptides; Parkinsonian Disorders; Piperidines; Pramipexole; Pyridines; Reaction Time; Receptors, Dopamine D3; Sulpiride | 2010 |
Continuous dopaminergic stimulation by pramipexole is effective to treat early morning akinesia in animal models of Parkinson's disease: A pharmacokinetic-pharmacodynamic study using in vivo microdialysis in rats.
Topics: Animals; Benzothiazoles; Catalepsy; Delayed-Action Preparations; Disease Models, Animal; Dopamine; Dopamine Agonists; Dyskinesia, Drug-Induced; Extracellular Space; Haloperidol; Infusion Pumps, Implantable; Injections, Subcutaneous; Male; Parkinson Disease; Parkinsonian Disorders; Photoperiod; Pramipexole; Rats; Rats, Wistar; Reserpine; Time Factors | 2010 |
Levodopa and pramipexole effects on presynaptic dopamine PET markers and estimated dopamine release.
Topics: Animals; Benzothiazoles; Biomarkers; Brain; Dopamine; Dopamine Agonists; Levodopa; Male; Parkinsonian Disorders; Positron-Emission Tomography; Pramipexole; Presynaptic Terminals; Rats; Rats, Sprague-Dawley | 2010 |
Selective IGT decision-making impairment in a patient with juvenile Parkinson's disease and pathological gambling: a role for dopaminergic therapy?
Topics: Adult; Antiparkinson Agents; Benzothiazoles; Cabergoline; Case-Control Studies; Compulsive Behavior; Decision Making; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Female; Gambling; Humans; Levodopa; Matched-Pair Analysis; Neuropsychological Tests; Parkinsonian Disorders; Pramipexole; Reference Values | 2012 |
Reinforcing properties of Pramipexole in normal and parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Benzothiazoles; Corpus Striatum; Dopamine Agonists; Drug-Seeking Behavior; Extinction, Psychological; Immunohistochemistry; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Pramipexole; Proto-Oncogene Proteins c-fos; Rats, Wistar; Receptors, Dopamine D2; Receptors, Dopamine D3; Reinforcement Schedule; Self Administration; Substance-Related Disorders | 2013 |
Drug-induced camptocormia: a lesson regarding vascular Parkinsonism.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Diagnostic Errors; Female; Humans; Muscular Atrophy, Spinal; Parkinsonian Disorders; Pramipexole; Spinal Curvatures; Vascular Diseases | 2012 |
Rebalance of striatal NMDA/AMPA receptor ratio underlies the reduced emergence of dyskinesia during D2-like dopamine agonist treatment in experimental Parkinson's disease.
Topics: Animals; Benzothiazoles; Corpus Striatum; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Excitatory Postsynaptic Potentials; Levodopa; Male; Neurons; Oxidopamine; Parkinsonian Disorders; Pramipexole; Rats; Rats, Wistar; Receptors, AMPA; Receptors, Dopamine D3; Receptors, N-Methyl-D-Aspartate | 2012 |
Acute onset of parkinsonism with reversible course after H1N1 vaccination: insight from a young lady.
Topics: Adolescent; Amantadine; Benzothiazoles; Drug Therapy, Combination; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Parkinsonian Disorders; Pramipexole; Treatment Outcome | 2012 |
Brain dopamine-serotonin vesicular transport disease and its treatment.
Topics: Age of Onset; Base Sequence; Benzothiazoles; Chromosomes, Human, Pair 10; Dopamine; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Dystonia; Female; Humans; Infant; Male; Molecular Sequence Data; Mood Disorders; Movement Disorders; Mutation; Parkinsonian Disorders; Pedigree; Pramipexole; Sequence Analysis, DNA; Serotonin; Serotonin Plasma Membrane Transport Proteins; Syndrome; Vesicular Monoamine Transport Proteins | 2013 |
Treatment effects on nigrostriatal projection integrity in partial 6-OHDA lesions: comparison of L-DOPA and pramipexole.
Topics: Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Autoradiography; Behavior, Animal; Benzothiazoles; Binding, Competitive; Corpus Striatum; Disease Models, Animal; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Motor Activity; Neuropeptides; Oxidopamine; Parkinsonian Disorders; Pramipexole; Rats; Rats, Sprague-Dawley; Substantia Nigra; Thiazoles; Treatment Outcome; Tritium; Vesicular Biogenic Amine Transport Proteins; Vesicular Monoamine Transport Proteins | 2003 |
Recovery from parkinson syndrome and prolonged visually evoked potentials in hepatic encephalopathy.
Topics: Anti-Bacterial Agents; Antiparkinson Agents; Benzothiazoles; Brain; Chronic Disease; Dipeptides; Evoked Potentials, Visual; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Lactulose; Levodopa; Male; Middle Aged; Parkinsonian Disorders; Paromomycin; Pramipexole; Recovery of Function; Thiazoles; Treatment Outcome; Vision Disorders | 2005 |
[Case of juvenile parkinsonism in pregnancy].
Topics: Adult; Antiparkinson Agents; Benzothiazoles; Cabergoline; Carbidopa; Contraindications; Dopamine Agents; Dopamine Agonists; Ergolines; Family Planning Services; Female; Humans; Infant, Newborn; Levodopa; Parkinsonian Disorders; Pramipexole; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Thiazoles | 2006 |
Neuroprotection in Parkinson models varies with toxin administration protocol.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antigens, Nuclear; Axons; Benzothiazoles; Biomarkers; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation, Preclinical; Male; Mice; Mice, Inbred C57BL; MPTP Poisoning; Nerve Degeneration; Nerve Tissue Proteins; Neurons; Neuroprotective Agents; Niacinamide; Parkinsonian Disorders; Pramipexole; Substantia Nigra; Tyrosine 3-Monooxygenase | 2006 |
Epilepsy, parkinsonism, and neuroleptic malignant syndrome in a child.
Topics: Anticonvulsants; Antiparkinson Agents; Aspartic Acid; Basal Ganglia; Benzothiazoles; Carbamazepine; Child; Electroencephalography; Epilepsy; Epilepsy, Complex Partial; Female; Humans; Magnetic Resonance Spectroscopy; Neuroleptic Malignant Syndrome; Parkinsonian Disorders; Phenytoin; Pramipexole; Time | 2006 |
Treatment of juvenile Parkinson disease and the recurrent emergence of pathologic gambling.
Topics: Adolescent; Adult; Antiparkinson Agents; Benzothiazoles; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Female; Gambling; Humans; Levodopa; Parkinsonian Disorders; Pergolide; Pramipexole; Recurrence | 2007 |
Changing dopamine agonist treatment in Parkinson's disease: experiences with switching to pramipexole.
Topics: Aged; Benzothiazoles; Dopamine Agonists; Female; Humans; Male; Motor Activity; Parkinsonian Disorders; Pramipexole; Product Surveillance, Postmarketing; Prospective Studies; Psychomotor Performance; Retrospective Studies; Severity of Illness Index; Tremor | 2006 |
Clinical characteristics of pramipexole-induced peripheral edema.
Topics: Adult; Aged; Aged, 80 and over; Benzothiazoles; Dopamine Agonists; Edema; Female; Humans; Male; Middle Aged; Parkinsonian Disorders; Peripheral Nervous System Diseases; Pramipexole; Retrospective Studies; Severity of Illness Index; Thiazoles | 2000 |
Pramipexole attenuates the dopaminergic cell loss induced by intraventricular 6-hydroxydopamine.
Topics: Animals; Benzothiazoles; Cell Count; Cell Death; Dopamine; Dopamine Agonists; Male; Neostriatum; Nerve Degeneration; Neurons; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Pramipexole; Rats; Rats, Sprague-Dawley; Substantia Nigra; Thiazoles | 2000 |
Comparative effects of repeated administration of dopamine agonists on circling behavior in rats.
Topics: Animals; Benzothiazoles; Brain; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Administration Schedule; Ergolines; Indoles; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Pergolide; Pramipexole; Rats; Rats, Sprague-Dawley; Reaction Time; Receptors, Dopamine D1; Receptors, Dopamine D2; Thiazoles | 2000 |
Neuroprotective effects of pramipexole in young and aged MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Antiparkinson Agents; Benzothiazoles; Cell Survival; Dopamine; Dopamine Agents; Fluorescent Dyes; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Neostriatum; Neural Pathways; Neurons; Neuroprotective Agents; Parkinsonian Disorders; Pramipexole; Stilbamidines; Substantia Nigra; Thiazoles; Tyrosine 3-Monooxygenase | 2001 |
Modafinil and pramipexole-associated somnolence.
Topics: Antiparkinson Agents; Benzhydryl Compounds; Benzothiazoles; Central Nervous System Stimulants; Disorders of Excessive Somnolence; Dopamine Agonists; Humans; Modafinil; Parkinsonian Disorders; Pramipexole; Thiazoles; Treatment Outcome | 2001 |
A case of Parkinsonism due to lithium intoxication: treatment with Pramipexole.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Dopamine Agonists; Female; Humans; Lithium; Parkinsonian Disorders; Pramipexole; Severity of Illness Index; Thiazoles | 2002 |